Plant-derived extracellular vesicles as a natural drug delivery platform for glioblastoma therapy: A dual role in preserving endothelial integrity while modulating the tumor microenvironment
Glioblastoma (GBM) is the most aggressive primary brain tumor, with limited treatment options due to the restrictive blood-brain barrier (BBB) and the heterogeneity of the blood-tumor barrier (BTB). Temozolomide (TMZ), the standard chemotherapy, suffers from poor BBB permeability, rapid degradation, and systemic toxicity. Plant-derived extracellular vesicles (PDEVs) have emerged as promising natural nanocarriers, offering biocompatibility, stability, and the ability to cross biological barriers. This study investigates the use of extracellular vesicles from <i>Citrus limon</i> L. (LDEs) to encapsulate and deliver TMZ (EVs@TMZ) for GBM treatment. LDEs were isolated, characterized, and loaded with TMZ via ultrasonication. Encapsulation efficiency, stability, and physicochemical properties were assessed using UV-Vis and FTIR spectroscopy. A 3D BTB model was developed using bioprinted U87 glioblastoma cells in Matrigel, co-cultured with hCMEC/D3 endothelial cells to replicate the tumor microenvironment. Barrier integrity was evaluated through TEER and FITC-dextran assays. Uptake, cytotoxicity, and tumor invasion were assessed in this model, along with oxidative stress and VEGF-A secretion. LDEs effectively encapsulated TMZ, enhancing drug stability under physiological conditions. EVs@TMZ crossed the endothelial barrier while preserving barrier integrity and reducing TMZ-induced ROS production. In the 3D glioblastoma model, EVs@TMZ showed strong cytotoxic effects on tumor cells while minimizing endothelial toxicity and oxidative stress. Moreover, VEGF-A secretion was suppressed, disrupting pro-tumorigenic pathways. These findings highlight Citrus-derived EVs as biocompatible, efficient carriers for TMZ delivery, offering a promising approach to overcome current challenges in GBM therapy and supporting further development of PDEVs for brain tumor treatment.
Authors
- Valentina Palmieri (ORCID: https://orcid.org/0000-0002-6358-9647)
- Antonio Minopoli (ORCID: https://orcid.org/0000-0001-5690-0604)
- Giordano Perini (ORCID: https://orcid.org/0000-0001-9452-8479)
- Marco De Spirito (ORCID: https://orcid.org/0000-0003-4260-5107)
- Massimiliano Papi (ORCID: https://orcid.org/0000-0002-0029-1309)
- Lishan Cui (ORCID: https://orcid.org/0000-0001-7647-1376)
Institutions
- Università Cattolica del Sacro Cuore (IT)
- Agostino Gemelli University Polyclinic (IT)
- Institute for Complex Systems (IT)
Publication Details
- Journal
- International Journal of Pharmaceutics X
- Published
- 2025-06-24
- DOI
- https://doi.org/10.1016/j.ijpx.2025.100349
- Citations
- 1
- Primary Topic
- Extracellular vesicles in disease
- Type
- article
- Field-Weighted Citation Impact
- 0.81
Funders
- Fondazione Umberto Veronesi